An observational study in Proton Therapy, Radiation Therapy, Secondary Skin Reactions and Liver Cancer, sponsored by University of Oklahoma. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by University of Oklahoma · Observational
Among 566 studies in Liver Neoplasms with a site in United States — 83 open to participants now, 122 under way, 6 of them phase 3. Liver Neoplasms · United States.
Among the 566 studies in Liver Neoplasms with a site in United States, this one is the 90th largest by planned enrollment of the 111 observational ones, is one of 19 that started in 2026, is one of 111 observational ones, reaches primary completion later than 88 of the 119 other live ones, and was the 565th registered.
1,345 studies on the registry are indexed under Liver Neoplasms; 335 are open to participants now.
This study's planned enrollment of 24 is below the median of 200 across 342 observational studies indexed under Liver Neoplasms.
Browse Liver Neoplasms studies →83 of the 566 studies in Liver Neoplasms with a site in United States are open now, in 12 countries. Each count lists the studies.
Of the 244 Liver Neoplasms studies recruiting now, 138 (57%) set no upper age limit and 69 (28%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →566 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 19 started in 2026.
Median enrollment 30 across the 433 interventional studies, 143 across the 111 observational. Of the 398 that completed or were terminated, 144 (36%) have results posted.
166 of 566 have an industry lead sponsor. The 10 most frequent:
University of Oklahoma is the lead sponsor of 432 studies on the registry; 100 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 16 (38%) have results posted.
University of Oklahoma has 2 studies filed under Liver Neoplasms — fewer than ten, so there is no comparison to draw.
40 of the studies in Liver Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02523443Phase 3Memorial Sloan Kettering Cancer CenterPatient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection | 2027-08 |
| NCT04390724Northwestern UniversityOptimizing Y90 Therapy for Radiation Lobectomy | 2026-11-27 |
| NCT00582647Memorial Sloan Kettering Cancer CenterCollection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract | 2026-12 |
| NCT07224464New Phase Ltd.The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. | 2026-12 |
| NCT07044362Case Comprehensive Cancer CenterHistotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis | 2026-12-01 |
Among the 566 studies in Liver Neoplasms with a site in United States, from their registry updates:
The purpose of this study is to test a new imaging technology called radioacoustic imaging (RAI) that may help doctors see where radiation is being delivered during proton therapy.
During proton therapy, the radiation treatment produces very small sound signals inside the body. This study will use special ultrasound sensors placed on the outside of the body to detect these signals. The information collected may allow researchers to create a picture showing where the radiation dose is being delivered in the body and how much radiation is reaching the treatment area.
The goal is to determine whether this technology can safely and accurately measure radiation during proton therapy without requiring any additional procedures or radiation exposure.
Radiation therapy is a cornerstone of cancer treatment, and proton therapy offers enhanced precision for treating deep-seated tumors due to the Bragg Peak phenomenon, which allows for concentrated dose delivery while minimizing exposure to surrounding healthy tissue. This study seeks to build upon this advantage by incorporating real-time, in vivo verification of proton dose deposition. The study hypothesizes that integrating RAI with ultrasound (US) will enable real-time dose verification and motion tracking, thereby improving the accuracy, adaptability, and overall effectiveness of proton therapy for moving targets such as the liver and prostate.
Participants enrolled in the study will first undergo standard X-ray alignment as part of their routine treatment workflow. Following alignment, a robotic arm will position an ultrasound matrix array over the lower anterior abdominal region. A conformal, water-mediated interface in combination with ultrasound gel will be used to ensure optimal acoustic coupling between the transducer and the patient's skin, allowing for passive detection of acoustic signals generated during proton beam delivery. These signals will be used to reconstruct and monitor dose deposition in real time throughout treatment.
Recruitment will be for prostate and liver cancer patients only.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This prospective clinical trial will evaluate the use of RAI in 24 cancer patients, including 12 patients with liver cancer and 12 patients with prostate cancer, using a noninvasive device. The device consists of a small ultrasound transducer placed on the participant's body that delivers low-intensity sound signals through the body to evaluate the treatment.
Device: Radiacoustic Imaging w/Ultrasound.
A robotic arm will position the ultrasound matrix array on the lower abdomen.
Percentage of Liver Cancer Patients With Successful Respiratory Motion From Radiacoustic Imaging Tracking.
The dual-modality Radioacoustic Imaging integrated with Ultrasound (RAI/US) system in liver cancer patients is deployed to track respiratory motion, overlay real-time dose maps on ultrasound anatomy, and integrate adaptive feedback into the treatment workflow.
Time frame: 1 year
Percentage of Completed Workflow Treatment Plans Using Radiacoustic Imaging With Ultrasound In Prostate Cancer Patients.
Successfully develop a time-efficient RAI/US workflow for daily prostate cancer treatments, monitoring both intra- and inter-fractional motion, and applying geometric corrections to support adaptive planning.
Time frame: 1 year
Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.
Of 132 non-industry observational studies under Liver Neoplasms, half reached primary completion within 114 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 172. This study's planned 24 months is below that.
Counting every sponsor, half of 160 studies reached it within 59 months; a quarter within 34 and three quarters within 172.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.